The Latest Psoriasis Industry Statistics Explained
Approximately 125 million people worldwide—2 to 3 percent of the total population—have psoriasis, according to current studies.
This statistic highlights the global prevalence of psoriasis, a chronic inflammatory skin condition characterized by red, scaly patches that can cause discomfort and affect quality of life. With approximately 125 million individuals worldwide estimated to be affected, representing about 2 to 3 percent of the total population, psoriasis is a significant health issue that impacts a substantial number of people. These figures emphasize the widespread nature of the condition and the need for awareness, research, and access to effective treatments to support those living with psoriasis and improve their overall well-being.
Studies have shown individuals with psoriasis can have a decreased quality of life similar to those with diseases such as cancer and heart disease.
The statistic suggests that individuals with psoriasis, a chronic skin condition characterized by red, itchy patches on the skin, may experience a decreased quality of life comparable to individuals affected by serious illnesses like cancer and heart disease. This implies that the physical and psychological burden of living with psoriasis can significantly impact various aspects of an individual’s well-being, such as their emotional health, social relationships, and overall quality of life. These findings underscore the importance of recognizing and addressing the holistic impact of psoriasis on affected individuals, highlighting the need for comprehensive care and support services to improve their overall health and well-being.
The global psoriasis treatment market was valued at USD 7.00 billion in 2015 and is expected to reach a value of USD 10.68 by 2022.
The statistic indicates that the global psoriasis treatment market had a value of USD 7.00 billion in 2015 and is projected to increase to USD 10.68 billion by 2022. This growth implies a compound annual growth rate (CAGR) over the period, reflecting an increasing demand for psoriasis treatment products and services worldwide. Factors contributing to this growth may include the rising prevalence of psoriasis, advancements in treatment options, increasing healthcare expenditure, and growing awareness among patients. The forecasted market value for 2022 suggests opportunities for pharmaceutical companies, healthcare providers, and other stakeholders in the psoriasis treatment market to develop innovative products and services to meet the evolving needs of patients with psoriasis.
Psoriasis drugs market in the United States is projected reach USD 13.3 billion by 2025.
The statistic that the Psoriasis drugs market in the United States is projected to reach USD 13.3 billion by 2025 suggests a significant growth in the market size for medications used to treat psoriasis within the next few years. This projection indicates a rising demand for psoriasis drugs in the United States, likely driven by increasing awareness and diagnosis of the condition, as well as advancements in treatment options. Pharmaceutical companies may see this as an opportunity for further investments and innovation in drug development for psoriasis, aiming to capture a larger share of the market and meet the growing needs of patients living with this chronic skin condition.
The prevalence of Psoriasis in the United States is approximately 7.5 million.
The statistic that the prevalence of Psoriasis in the United States is approximately 7.5 million means that an estimated 7.5 million people in the country are affected by the skin condition known as Psoriasis. Prevalence refers to the proportion of a population that has a particular disease or condition at a specific point in time. In this case, the statistic suggests that Psoriasis is relatively common in the United States, affecting a significant number of individuals. Understanding the prevalence of Psoriasis is important for healthcare professionals, policymakers, and researchers to allocate resources effectively and develop targeted interventions to support individuals living with this chronic condition.
From 2020 to 2025, the psoriasis therapeutics market is expected to grow at a 7.3% CAGR.
This statistic indicates that the psoriasis therapeutics market is projected to experience significant growth over the period from 2020 to 2025, with a compound annual growth rate (CAGR) of 7.3%. A CAGR of 7.3% suggests a steady upward trajectory in market size and value over the given timeframe. This growth rate reflects the anticipated increase in demand for therapeutics to treat psoriasis during this period. Factors such as advancements in treatment options, increasing prevalence of psoriasis, and rising awareness and acceptance of available therapies could be driving this growth. The projection of a 7.3% CAGR provides insights into the potential opportunities and trends within the psoriasis therapeutics market for investors, stakeholders, and healthcare providers to consider for strategic planning and decision-making.
North America is projected to account for the largest share of the global psoriasis therapeutics market in 2020.
This statistic indicates that North America is expected to have the highest market share in the global psoriasis therapeutics market in 2020, outpacing other regions worldwide. This suggests that the demand for psoriasis treatment in North America is significant, potentially due to factors such as a higher prevalence of the condition, greater awareness and diagnosis rates, and a higher adoption of advanced treatments. As a result, pharmaceutical companies and healthcare providers may focus more resources and efforts in North America to cater to this demand and potentially drive innovation in the field of psoriasis therapeutics.
Approximately 3% of the world population has some form of psoriasis.
The statistic that approximately 3% of the world population has some form of psoriasis indicates the prevalence of this chronic skin condition on a global scale. Psoriasis is a common autoimmune disorder characterized by the rapid growth of skin cells, leading to red, scaly patches on the skin that can be itchy and painful. This statistic highlights the significant impact of psoriasis, affecting millions of people worldwide. Understanding the prevalence of psoriasis can aid in raising awareness, improving access to treatment and support services, and guiding public health initiatives aimed at addressing this condition.
Up to 30% of people with psoriasis will eventually develop psoriatic arthritis.
The statistic “Up to 30% of people with psoriasis will eventually develop psoriatic arthritis” indicates the risk of individuals with psoriasis progressing to develop an associated condition known as psoriatic arthritis. Psoriasis is a chronic skin condition characterized by red, scaly patches on the skin, while psoriatic arthritis is an autoimmune disease that affects the joints. The statistic suggests that there is a significant overlap between these two conditions, with up to 30% of individuals with psoriasis ultimately developing psoriatic arthritis. This highlights the importance of monitoring patients with psoriasis for symptoms of arthritis and providing early intervention to manage and treat this potentially debilitating condition.
Among those living with psoriasis, about 80% have moderate to severe disease.
The statistic reveals that within the population of individuals who are living with psoriasis, approximately 80% of them have been diagnosed with moderate to severe cases of the skin condition. This suggests that a significant majority of psoriasis patients experience symptoms that are beyond mild or easily manageable, indicating a higher degree of severity that may require more intensive treatment and management strategies. Understanding this statistic is crucial for healthcare providers, researchers, and policymakers to allocate appropriate resources and support to address the specific needs and challenges faced by individuals with moderate to severe psoriasis in order to improve their quality of life and overall health outcomes.
An estimated 20% of psoriasis cases among adults were moderate to severe as of 2005.
This statistic indicates that in 2005, approximately 20% of adults diagnosed with psoriasis had moderate to severe forms of the condition. Psoriasis is a common skin disorder characterized by red, scaly patches that can be mild, moderate, or severe in nature. Moderate to severe psoriasis typically covers a larger area of the body and may require more aggressive treatment approaches compared to mild cases. This statistic provides important information about the distribution of psoriasis severity among adults in 2005, serving as a benchmark for understanding the impact of the condition and guiding healthcare resources and interventions for individuals with moderate to severe psoriasis.
The psoriasis drug industry is predicted to rise at a CAGR of 9.79% between 2021 and 2026.
This statistic indicates that the market size of the psoriasis drug industry is expected to experience a Compound Annual Growth Rate (CAGR) of 9.79% over the period from 2021 to 2026. This projected growth rate suggests a steady and substantial increase in the market demand and revenue generated by psoriasis medications over the next five years. Factors such as a rising prevalence of psoriasis, advancements in drug development, increasing awareness and acceptance of treatment options, and a growing aging population are likely contributing to this anticipated growth in the industry. This forecast can be valuable for stakeholders in the pharmaceutical and healthcare sectors to make informed decisions regarding investment, research, and strategic planning related to the development and distribution of psoriasis drugs.
Adults with severe psoriasis can die on average 3 to 5 years earlier than those without the disease.
The statistic that adults with severe psoriasis can die on average 3 to 5 years earlier than those without the disease suggests a significant impact of psoriasis on life expectancy. Psoriasis is a chronic autoimmune condition that causes inflammation and thick, red skin patches, and severe forms of the disease can lead to a higher risk of developing comorbidities such as cardiovascular disease, diabetes, and other chronic conditions. The early mortality associated with severe psoriasis may be attributed to these associated health complications and the overall burden on the immune system and body. This statistic highlights the importance of managing and treating psoriasis effectively to potentially reduce the risk of premature death among affected individuals.
Psoriasis often appears between the ages of 15 and 25, but can develop at any age.
This statistic highlights the typical age range of onset for psoriasis, a chronic skin condition characterized by red, scaly patches that can be itchy and painful. The statement indicates that psoriasis most commonly emerges during adolescence or early adulthood, with a peak between 15 and 25 years of age. However, it emphasizes that psoriasis is not limited to this age group and can develop at any time throughout a person’s life. This information underscores the variability in the onset of psoriasis and the importance of vigilance for symptoms regardless of age, as early detection and management are crucial in effectively treating the condition.
Studies show that between 10 and 30 percent of people with psoriasis also develop psoriatic arthritis.
This statistic indicates that a substantial proportion of individuals diagnosed with psoriasis, a chronic skin condition characterized by red, scaly patches, may also develop psoriatic arthritis, an inflammatory joint disease. The range of 10 to 30 percent suggests variability in the likelihood of developing psoriatic arthritis among individuals with psoriasis. This statistic underscores the association between these two conditions and highlights the importance of monitoring and managing both skin and joint symptoms in individuals with psoriasis to improve overall health outcomes and quality of life.
Europe is expected to account for the second-largest share in the psoriasis therapeutics market.
This statistic suggests that Europe is projected to have the second-highest market share in the psoriasis therapeutics market, following another region that holds a larger share. The statement implies that Europe is a significant market for psoriasis treatments, likely due to factors such as the prevalence of psoriasis in the region, access to healthcare services, and advancements in medical research and development. As a result, pharmaceutical companies and healthcare providers may prioritize the European market when developing and promoting psoriasis treatments, recognizing the potential for significant sales and revenue in this region.
According to the World Health Organization, nearly 60% of psoriasis sufferers report their disease to be a large problem in their everyday life.
The statistic from the World Health Organization stating that nearly 60% of psoriasis sufferers report their disease to be a significant problem in their everyday life highlights the substantial burden that psoriasis can impose on individuals. This statistic indicates that a majority of individuals living with psoriasis experience significant impacts on various aspects of their daily lives, such as physical discomfort, emotional distress, and social challenges. The finding underscores the importance of addressing not only the physical symptoms of psoriasis but also the broader impact it has on the overall well-being and quality of life of those affected. It emphasizes the need for comprehensive support and management strategies to improve the holistic well-being of individuals navigating the challenges of living with psoriasis.
By 2027, the global psoriasis drugs market is predicted to reach USD 24.1 billion.
The statistic indicates that the global market for psoriasis drugs is forecasted to grow significantly by the year 2027, reaching a value of USD 24.1 billion. This prediction suggests a substantial increase in the demand for psoriasis medications, likely driven by factors such as a rising prevalence of psoriasis worldwide, increasing awareness about the condition, and advancements in drug development for treating psoriasis. The projected market value serves as an important indicator for pharmaceutical companies, healthcare providers, policymakers, and other stakeholders in understanding the market dynamics and planning for future investments and strategies related to psoriasis treatment and management.
Plaque psoriasis is the most common form of psoriasis, accounting for about 90% of reported cases.
The statistic indicating that plaque psoriasis is the most common form of psoriasis, accounting for about 90% of reported cases, reflects the prevalence and significance of this particular subtype within the psoriasis spectrum. Plaque psoriasis is characterized by raised, red patches covered with a buildup of dead skin cells, which can be itchy and uncomfortable for individuals affected by it. Its predominance suggests that it is the most frequently diagnosed and studied form of psoriasis, emphasizing the importance of understanding and effectively managing this condition given its high prevalence in psoriasis patients. By focusing on plaque psoriasis, researchers and healthcare practitioners can better tailor treatments and interventions to address the needs of a vast majority of individuals with psoriasis.
Approximately 1 in 3 people with psoriasis report having a relative with the disease.
The statistic “Approximately 1 in 3 people with psoriasis report having a relative with the disease” suggests a familial connection in the prevalence of psoriasis. Specifically, it implies that there is a genetic component to the development of psoriasis, as individuals with a family history of the condition are more likely to develop it themselves. This statistic highlights the potential hereditary nature of psoriasis and emphasizes the importance of considering family history when assessing an individual’s risk of developing the disease. Furthermore, this information may be valuable in understanding the underlying causes of psoriasis and identifying individuals who may be at a higher risk of developing the condition.
References
0. – https://www.www.ncbi.nlm.nih.gov
1. – https://www.www.marketsandmarkets.com
2. – https://www.www.who.int
3. – https://www.www.fortunebusinessinsights.com
4. – https://www.www.globenewswire.com
5. – https://www.www.psoriasis.org
6. – https://www.www.mayoclinic.org
7. – https://www.www.grandviewresearch.com
8. – https://www.www.aad.org
9. – https://www.www.prnewswire.com
10. – https://www.www.mordorintelligence.com
